Zetia
AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.
If you or a loved one are in need of legal assistance concerning Zetia you should get a lawyer on your side immediately. You will pay no attorney fees unless you win your case.
Email up to 10 Zetia law firms in one click; by filling out the simple Free Case Evaluation form.
For additional info on Zetia use the related topic links on the far right.
Zetia
If you or a family memeber has been effected by Zetia or the side effects of Zetia you may have a case.
Zetia is a drug designed to lower cholesterol levels – specifically to lower the level of LDL or “bad cholesterol.” The drug takes a different scientific approach to lowering cholesterol levels and has been widely prescribed as an addition to an existing program of treatment with one of the “statin” drugs such as Zocor or Lipitor. Zetia has been marketed jointly by Merck Laboratories and Schering-Plough and has been an important success in the market since the FDA approved it in October of 2002.
The goal of all cholesterol medication is to lower the possibility of plaque developing in critical heart arteries – blockages that can lead to cardiovascular “events” such as a stroke or a heart attack. Zetia has shown remarkable results in both lowering LDL counts in heart patients and in raising HDL (“good cholesterol”) levels at the same time. The drug has been widely prescribed and looked upon as a substantial step in the control of arteriosclerosis (arterial blockage).
However there have been questions raised recently about Zetia’s ability to influence the effect of lowered LDL levels on plaque reduction. Moreover, there have been concerns about Zetia’s possible impact on the liver. The two drug companies who have been marketing Zetia did an extensive field study on the medication after it had been on the market for a while, and while they had all the data in hand by 2006 they declined to publicly release any information.
The study showed that while Zetia works well reducing high cholesterol levels, there is no correlating evidence of a reduction in cardiovascular “incidents” as there was in the clinical studies of the “statin” drugs. Moreover, there is apparently some indication that the data shows increased liver enzyme levels as the result of combining Zetia with a statin drug.
IN December of 2007, the New York Times published an article about the completed study – named ENHANCE – and the reluctance of the two drug companies to make their data public. The FDA has seen the report and has thus far declined to issue any warnings. That has not been the case in Canada, Australia and other companies however. Both those countries issued warnings in 2005 about potential liver damage, hepatitis, pancreatitis and depression from the use of Zetia.
While there is no definitive long-term test available on the drug, some physicians are taking precautions with it, using it as a last resort if the patient for some reason cannot tolerate a statin drug. The drug companies have launched a long term, 10,000 patient study of Zetia’s effectiveness and potential dangers, but the data will not be available until 2011.
Zetia In The News
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.
Citigroup analyst lowers forecast for key Merck targetsShares of drugmaker Merck & Co. fell about 2 percent Wednesday after an analyst lowered his forecast for key financial targets, but shares recovered somewhat in late morning trading.
Citigroup analyst cuts target for Merck salesShares of drugmaker Merck & Co. fell about 2 percent Wednesday after an analyst lowered his forecast for key financial targets, but shares recovered and even advanced by the end of the trading session.
Merck shares hurt after analyst lowers forecastShares of Readington-based drugmaker Merck & Co. fell about 2 percent today after an analyst lowered his forecast for key financial targets, but shares recovered somewhat in late morning trading.
N.J. drugmaker says it's in good shape to compete with new productsKenilworth-based Schering-Plough Corp. has many promising drugs in late testing and years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts today.
Schering’s Hassan Looks Past Vytorin, Touts Research (Update2)Nov. 24 (Bloomberg) -- Schering-Plough Corp. plans to begin selling products in the next four years that may generate more than $7 billion in combined annual revenue, lessening the company’s dependence on embattled cholesterol pills.
Schering-Plough touts its drug lineup at analyst meeting.Schering-Plough has many promising drugs in late testing and years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts today.Jennifer Brown/The Star-LedgerSchering-Plough CEO Fred Hassan said the Kenilworth drugmaker is well-positionedThe...
(AFX UK Focus) 2008-11-24 19:46 UPDATE 1-Schering-Plough touts drug pipeline 'stars'By Ransdell Pierson and Lewis Krauskopf
Schering-Plough touts pipeline over competitors'KENILWORTH, N.J. - Schering-Plough Corp. has many promising drugs in late testing and years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday.
Schering-Plough touts pipeline over competitors'Schering-Plough Corp. has many promising drugs in late testing, three awaiting approval, plus years of patent protection for its key products, unlike most of its competitors, Chief Executive Fred Hassan told analysts Monday. The drugmaker has three drugs awaiting U.S. approval and nine more in final human testing - including a new type of anticlotting drug that could grab some of blockbuster ..
